Search 

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your in-licensing strategy and how we might work together.

CUBIC is the ultimate platform for emerging and growing companies seeking to expand their market to China or establish a business presence in China through various services and programs fitting every clients' needs and stage. When vacationing abroad, your best guide is a native, and business is no different. As CUBIC is owned by one of the largest Chinese incubator Thinkzone, you can be confident that you will be benefiting from one of the most extensive and influential networks in China.

Deutsche Bank is the largest bank in Germany and one of only 4 Depositary Receipt banks able to list Life Sciences and Medtech companies on US exchanges using ADRs.

Manufacturing, whole sale innovation product EYEIMPROVER.com - the stimulator for the eyes

Distributer for pharmaceutical products

Enosi's lead programs involve novel inhibitors of TNF (tumor necrosis factor), which include severe inflammation associated with viral infections, autoimmune disease, fibrotic diseases, Alzheimer’s, cancer and other diseases. The current TNF inhibitors have important “Black Box” warnings for opportunistic infections, cancer, and cardiovascular events, like stroke. Enosi believes our compounds in development will avoid these limitations of current drugs, be more effective, and will allow expansion into many indications/markets that cannot be approached at the present time by current TNF inhibitors because of their side-effects.

Real-time Data Aggregation and analytics in real-time

We support companies gather information and analyze information in real-time speed access to insight facts and evidence into suppliers, vendors. partners and customers